Announcements Trials
Browse Landscape

Phase

Phase NA 12Phase 3 4Phase 2 3Phase 4 2Phase 1/2 1

Status

Unknown 1Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 157Neoplasms 115Colorectal Neoplasms 97Breast Neoplasms 90Pancreatic Neoplasms 81Leukemia, Myeloid, Acute 81Recurrence 78Neoplasm Metastasis 78Prostatic Neoplasms 73Melanoma 73Ovarian Neoplasms 72Multiple Myeloma 66Stomach Neoplasms 60Squamous Cell Carcinoma of Head and Neck 55Lung Neoplasms 55Triple Negative Breast Neoplasms 50Glioblastoma 48Lymphoma 47Endometrial Neoplasms 43Carcinoma, Hepatocellular 43Advanced Solid Tumor 43Precursor Cell Lymphoblastic Leukemia-Lymphoma 42Lymphoma, Non-Hodgkin 41Advanced Solid Tumors 37Uterine Cervical Neoplasms 35Small Cell Lung Carcinoma 35Carcinoma, Renal Cell 34Lymphoma, Large B-Cell, Diffuse 32Lymphoma, B-Cell 32Sarcoma 29

Interventions

sulforaphane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × Cardiotoxicity × Clear all
NCT03934905 2024-11-20

Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction

Texas Tech University Health Sciences Center

Phase 1/2 Recruiting
70 enrolled

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡